REPL
Replimune Group Inc
NASDAQ · Biotechnology
$7.75
+0.82 (+11.83%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| EPS | — | — | — |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| Rev Growth | -3.7% | +3.8% | +9.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 349.99M | 286.09M | 339.78M |
| Total Equity | 338.62M | 342.02M | 366.57M |
| D/E Ratio | 1.03 | 0.84 | 0.93 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |